Benefits of Pravastatin on Cardiovascular Events and Mortality in Older Patients with Coronary Heart Disease Are Equal to or Exceed Those Seen in Younger Patients: Results from the LIPID Trial
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effect of cholesterol-lowering therapy on death from coronary heart disease in older patients with previous coronary heart disease and average cholesterol levels is uncertain. OBJECTIVE: To compare the relative and absolute effects of pravastatin on cardiovascular disease outcomes in patients with coronary heart disease who are 65 years of age or older with those in patients 31 to 64 years of age. DESIGN: Subgroup analysis of a randomized, placebo-controlled trial. SETTING: 87 centers in Australia and New Zealand. PATIENTS: 3514 patients 65 to 75 years of age, chosen from among 9014 patients with previous myocardial infarction or unstable angina and a baseline plasma cholesterol level of 4.0 to 7.0 mmol/L (155 to 271 mg/dL). INTERVENTION: Pravastatin, 40 mg/d, or placebo. MEASUREMENTS: Major cardiovascular disease events over 6 years. RESULTS: Older patients were at greater risk than younger patients (31 to 64 years of age) for death (20.6% vs. 9.8%), myocardial infarction (11.4% vs. 9.5%), unstable angina (26.7% vs. 23.2%), and stroke (6.7% vs. 3.1%) (all P < 0.001). Pravastatin reduced the risk for all cardiovascular disease events, and similar relative effects were observed in older and younger patients. In patients 65 to 75 years of age, pravastatin therapy reduced mortality by 21% (CI, 7% to 32%), death from coronary heart disease by 24% (CI, 7% to 38%), coronary heart disease death or nonfatal myocardial infarction by 22% (CI, 9% to 34%), myocardial infarction by 26% (CI, 9% to 40%), and stroke by 12% (CI, -15% to 32%). For every 1000 older patients treated over 6 years, pravastatin prevented 45 deaths, 33 myocardial infarctions, 32 unstable angina events, 34 coronary revascularization procedures, 13 strokes, or 133 major cardiovascular events, compared with 22 deaths and 107 major cardiovascular events per 1000 younger patients. Among older patients, the numbers needed to treat were 22 (CI, 17 to 36) to prevent one death from any cause, 35 (CI, 24 to 67) to prevent one death from coronary heart disease, and 21 (CI, 17 to 31) to prevent one coronary heart disease death or nonfatal myocardial infarction. CONCLUSIONS: In older patients with coronary heart disease and average or moderately elevated cholesterol levels, pravastatin therapy reduced the risk for all major cardiovascular events and all-cause mortality. Since older patients are at greater risk than younger patients for these events, the absolute benefit of treatment is significantly greater in older patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“per 1000 persons treated, 45 deaths and 47 major coronary events would be prevented in the older group over 6 years compared with 22 deaths and 32 major coronary events in younger patients over the same time period.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [334]
In the citing paper
“Similar results were found in subgroup analyses of the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID), 334 Cholesterol and Recurrent Events (CARE) 335 and TNT trials. 336”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [334]
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · cited 1×
“2 mmol/L [240 mg/dL] in the Cholesterol and Recurrent Events [CARE] trial) (9, 10).”
BackgroundMurray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07492-2 · Cited by 7,007
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Sans, S., Kesteloot, H., Kromhout, D., & on behalf of the Task Force (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015434 · Cited by 785
Davis, B. (1996) · American Journal of Hypertension · doi:10.1016/0895-7061(96)00037-4 · Cited by 595
Miettinen, T. A., Pyörälä, K., Olsson, A. G., Musliner, T. A., Cook, T. J., Faergeman, O., Berg, K., Pedersen, T., Kjekshus, J., & Group, F. T. S. S. S. (1997) · Circulation · doi:10.1161/01.cir.96.12.4211 · Cited by 508 · cited 2×
“Data from 4S showed similar changes in cholesterol levels with simvastatin therapy in older and younger patients (18).”
BackgroundTotal cholesterol and risk of mortality in the oldest old
Weverling-Rijnsburger, A. W., Blauw, G. J., Lagaay, A. M., Knock, D. L., Meinders, A. E., & Westendorp, R. G. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04430-9 · Cited by 474
The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
Shepherd, J., Blauw, G. J., Murphy, M. B., Cobbe, S. M., Bollen, E. L. E. M., Buckley, B. M., Ford, I., Jukema, J. W., Hyland, M., Gaw, A., et al. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00533-0 · Cited by 449
Research works printed but not linked: 1
- 1994, Lancet, 344, 1383
Cited by
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Long-term persistence in use of statin therapy in elderly patients
Benner, J. S. (2002) · JAMA · doi:10.1001/jama.288.4.455 · Cited by 1,232
Alexander, K. P., Newby, L. K., Cannon, C. P., Armstrong, P. W., Gibler, W. B., Rich, M. W., Van de Werf, F., White, H. D., Weaver, W. D., Naylor, M. D., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.182615 · Cited by 914
Metadata
- Authors
- Hunt, D., Young, P., Simes, J., Hague, W., Mann, S., Owensby, D., Lane, G., Tonkin, A., & for the LIPID Investigators
- Affiliations
- The University of Sydney (AU)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2001-05-15
- Volume
- 134
- Issue
- 10
- Pages
- 931-940
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2057721505
- Cited by
- 226
- References
- 24
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 3 · 2022: 3 · 2020: 7 · 2019: 11 · 2018: 4 · 2017: 3 · 2016: 8 · 2015: 7 · 2014: 9 · 2013: 10 · 2012: 6
- FWCI
- 17.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- pravastatin, coronary artery disease, elderly patients, cholesterol-lowering therapy, cardiovascular mortality, myocardial infarction, unstable angina, stroke, subgroup analysis, LIPID trial, statins, age differences in treatment response, coronary revascularization, hypercholesterolemia, secondary prevention, cardiovascular risk stratification
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Cause of Death, Coronary Disease, Female, Humans, Hypercholesterolemia, Male, Middle Aged, Prospective Studies, Risk Factors, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefits of Pravastatin on Cardiovascular Events and Mortality in Older Patients with Coronary Heart Disease Are Equal to or Exceed Those Seen in Younger Patients: Results from the LIPID Trial. https://app.cochat.ai/papers/10.7326/0003-4819-134-10-200105150-00007
- The paper
- Hunt, D., Young, P., Simes, J., Hague, W., Mann, S., Owensby, D., Lane, G., Tonkin, A., & for the LIPID Investigators. (2001). Benefits of Pravastatin on Cardiovascular Events and Mortality in Older Patients with Coronary Heart Disease Are Equal to or Exceed Those Seen in Younger Patients: Results from the LIPID Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-134-10-200105150-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.